Symeres Acquires Exemplify Biopharma, Further Strengthening Its Strategic Foothold In The Us
Acquiring Company
Symeres
Acquired Company
Exemplify BioPharma
NijmegenBiotechnologyHealth CareresearchBiotechnologyHealth CarePharmaceuticalDescription
Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), today announces the acquisition of Exemplify BioPharma (or "Exemplify"), a US based CRO that provides integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners.
Quick answer
Symeres is acquiring Exemplify BioPharma, announced October 25, 2022. Symeres is based in Nijmegen, Gelderland, Netherlands.
- How much did Symeres pay for Exemplify BioPharma?
- The deal value was not disclosed.
- What does Symeres do?
- Symeres is a leading mid-sized transatlantic Contract Research Organization (CRO) specializing in drug discovery and development.
- Where are Symeres and Exemplify BioPharma based?
- Symeres is based in Nijmegen, Gelderland, Netherlands.
- Who are the decision-makers at Symeres?
- Fundz holds 1 contact at Symeres. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in research and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Sumitovant Biopharma And Sumitomo Pharma Announce Offer To Acquire Outstanding Shares Of Myovant Sciences (October 2, 2022)
- Lilly Completes Acquisition Of Akouos Expanding Efforts To Help People With Genetic Diseases (December 1, 2022)
- Merck To Acquire Imago Biosciences, Inc. (November 21, 2022)
- Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy (November 1, 2022)
- Amgen Successfully Completes Acquisition Of Chemocentryx (October 20, 2022)
- Lilly To Acquire Akouos To Discover And Develop Treatments For Hearing Loss (October 18, 2022)
Who to call at Symeres, and when
When Symeres changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Symeres raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Symeres, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Symeres. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Symeres makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Exemplify BioPharma?
Exemplify BioPharma was acquired by Symeres, based in Nijmegen. The deal was reported on October 25, 2022. Symeres is a leading mid-sized transatlantic Contract Research Organization (CRO) specializing in drug discovery and development. With about 600 scientists across six European sites and two U.S. Symeres is privately held and operates in Biotechnology.
When did Symeres acquire Exemplify BioPharma?
Symeres's acquisition of Exemplify BioPharma was reported on October 25, 2022. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Exemplify BioPharma do?
Exemplify BioPharma is a Global Partnership Organization (GPO), founded in 2015, and based in New Jersey (US). It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.